EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSATEG00000011967
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSATEG00000003880
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSATEG00000014598
Gene Symbol: ADAM17A
1 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSATEG00000002612
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSATEG00000028063
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Aph1b Gamma Secretase Subunit

Ensembl ID : ENSATEG00000016694
Gene Symbol: APH1B
2 Cross references
193 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSATEG00000018989
Gene Symbol: ABCC8
1 Cross references
227 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSATEG00000013536
Gene Symbol: ATP4B
4 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSATEG00000015436
Gene Symbol: ATP1A2A
3 Cross references
205 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1a

Ensembl ID : ENSATEG00000029473
Gene Symbol: ATP1B1A
2 Cross references
216 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1b

Ensembl ID : ENSATEG00000011557
Gene Symbol: ATP1B1B
2 Cross references
215 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSATEG00000014533
Gene Symbol: ATP1B2B
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).